Lausanne, Switzerland
MindMaze Therapeutics is positioning itself as a formidable player in the digital neuro-therapeutics sector, with the mission captured in its slogan: "Accelerating humanity’s ability to recover, learn and adapt through advanced neuroscience and digital therapeutics." The company, founded in 2012 by Dr. Tej Tadi, stands out as a pioneer in using cutting-edge technology across neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence.
Headquartered in Switzerland, this company has established itself as the first Swiss Unicorn, expanding its influence with offices in cities like Lausanne, Baltimore, London, Paris, and Mumbai. MindMaze addresses vital neurological issues, such as stroke and Alzheimer's, through its FDA-cleared and CE-marked digital therapeutic solutions.
The recent influx of $105 million during a Venture Round on February 17, 2022, from investors like Hambro Perks, AlbaCore Capital Group, and Concord Health Partners, underscores the confidence in MindMaze's potential to transform brain health recovery.
